Iberdomide hydrochloride

• CAT Number: I029032
• CAS Number: 1560678-63-8
• Molecular Formula: C25H28ClN3O5
• Molecular Weight: 485.96
• Purity: 98%
• Synonyms: CC-220 hydrochloride; CC-220 HCl; Iberdomide hydrochloride; Iberdomide HCl
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride
• InChI: InChI=1S/C25H27N3O5.ClH/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27;/h1-7,21H,8-16H2,(H,26,29,30);1H/t21-;/m0./s1
• InChIKey: VVHQVXXPZDALDV-BOXHHOBZSA-N
• SMILES: C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5.Cl

Iberdomide hydrochloride（Cat No.:I029032）is a potent, oral immunomodulatory drug under investigation for the treatment of multiple myeloma and other hematologic malignancies. It is a derivative of lenalidomide and works by modulating the immune system to promote anti-tumor activity. Iberdomide hydrochloride targets cereblon, a key component of the E3 ubiquitin ligase complex, leading to the degradation of specific proteins that inhibit immune response. Early clinical trials have shown promising results in enhancing the activity of immune cells, potentially improving outcomes for patients with difficult-to-treat cancers.